leisure time -WSS

leisure time

author：focus 2025-08-23 06:45:04 - browse：4623

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Despite FDA approval for Lyfgenia, Bluebird faces stiff competition

Wikipedia

WSS

FDA needs staff influx to meet gene therapy needs, Marks says

Celebrate National Dole Whip Day for 3 days this week at Disney

Trump got a 'target letter.' What is one and what does it mean?

How dance can help health care workers heal from trauma

States increasingly look to regulate hospital facility fees

'Reaching a detente': STAT's Helen Branswell on covering Covid

focus

leisure time

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA approves world's first CRISPR

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

TikTok cracks down on users posting about weight loss drugs

Tori Bowie and the unacceptable rates of Black maternal death

CMS should re

Supreme Court strikes down use of affirmative action

Trump got a 'target letter.' What is one and what does it mean?

Medicare details structure of new drug price negotiation program

Roche to buy Carmot Therapeutics, developer of obesity drugs

focus

Spinal cord stimulation reduces pain in amputees, study finds

CMS should re

The kidney, in all its complexity, is captured in a new atlas

FDA needs staff influx to meet gene therapy needs, Marks says

Seattle police shoot person suspected in downtown stabbing

DOJ, FTC to increase scrutiny of all types of health care mergers

hotspot

leisure time

Wikipedia

focus